• Hapvida clarified its contract repricing review covers about 947,000 beneficiaries, with repricing or discontinuation expected over the next 12 months.
• Terms remain undefined, non-uniform, contract-by-contract, region-by-region; renegotiations may include plan changes or copayment adjustments, not only price.
• “Strong double-digit” was described as a reference to past premium increases, not guidance on upcoming adjustments; some media misquoted it as “high double-digit.”
• The phrase was used to counter an assumption that the review would necessarily cut revenue; past strong double-digit increases did not automatically reduce revenue.
• Hapvida stated it sees no undisclosed material fact on the topic under CVM rules.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hapvida Participações e Investimentos SA published the original content used to generate this news brief on August 25, 2026, and is solely responsible for the information contained therein.